NEW YORK (GenomeWeb News) – Atossa Genetics said after the close of the market on Thursday that its full-year 2013 revenues grew 31 percent year over year on increased product sales.

The Seattle-based firm recorded $632,558 in total revenues for 2013, up from $481,842 in 2012. While diagnostic testing service revenues slipped to $409,118 from $475,402, product sales rose to $223,440 from $6,440, Atossa said, noting that $205,590 in product sales resulted from the purchase of 10,000 ForeCYTE specimen collection kits by Millennium Healthcare.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.